Bristol Myers shows modest revenue rise, Biogen beats forecasts, Regeneron outlook remains uncertain

BioPharma Dive highlighted the latest quarterly earnings from three major biotech firms, noting how investors are interpreting the results.

Bristol Myers Squibb reported $11.5 billion in revenue for the first quarter, a 3 percent increase year-over-year, driven mainly by its legacy portfolio of established drugs such as Opdivo, Yervoy, Orencia and Reblozyl. Analysts said the figure topped estimates by about $572 million, though some newer products fell short of expectations.

Biogen saw its stock rise after newer therapies, including Leqembi and Skyclarys, delivered better-than-expected performance, giving the company a more optimistic outlook.

Regeneron’s update was less encouraging, with investors expressing concern over the company’s pipeline and future growth prospects.